Your position:m.limatoxi.com >> EN >> EN >> Formulation >> Amgen to present results from phase 4 FOREMOST study of Otezla to treat early oligoarticular psoriatic arthritis at ACR 2023 >> article
 
Amgen to present results from phase 4 FOREMOST study of Otezla to treat early oligoarticular psoriatic arthritis at ACR 2023
Editor:xuezhe     Clicks:0    Date:2023-11-9 15:38:49
Keyword: ACR
Healthoo Information:
Amgen to present results from phase 4 FOREMOST study of Otezla to treat early oligoarticular psoriatic arthritis at ACR 2023
 
 E-mail:xuezhe@healthoo.com
 Tel.:86-10-68032463
　　Our services:
 China Im\Ex data service
 Service fees of Chinese Vision
 Our service items
Online information introduction
Monthly information
Relative Information
  • Reasons for the sales growth of macrolides in Guo Bang Pharmaceutical ...
  • Analysis of 70 macrocyclic drugs approved by the FDA
  • Market Analysis of Macrolide Raw Materials
  • Indian import volumes of Macrolides in Jan. 2021
  • Import volumes of Macrolides APIs in India in Jul 2020
  • India import statistics of Macrolide APIs
  • Macrolides drugs rank in sample drugstores in March 2020
  • Hisun got Piracetam CEP certificate of Tacrolimus
  • HEC outputs of macrolide antibiotics in 2018
  • Macrolides export volumes in Jan-Sep 2018
    • Address: Suite 13F,NO2 Building, FuXing International, TianHua North Street, Yizhuang, Daxing District, Beijing, P.R. China
    Tel:+86-10-68032463
    Baidu
    map